HOME >> MEDICINE >> NEWS
Dutch study highlights short-term and long-term options for treatment of tennis elbow

N.B. Please note that if you outside North America the embargo date for Lancet press material is 0001 hours UK time Friday 22 February 2002.

Authors of a study in this weeks issue of THE LANCET conclude that steroid injections offer the best short-term treatment for tennis elbow, with physiotherapy offering marginally better long-term results than a wait-and-see policy.

Tennis elbow (lateral epicondylitis) affects 1-3% of the adult population; symptoms usually last between 6 months and two years, with most patients making a full recovery. The condition is generally treated with corticosteroid injections or physiotherapy. However, Dutch clinical guidelines recommend a wait-and-see policy.

Nynke Smidt and colleagues from Vrije University, Amsterdam, Netherlands, studied patients with tennis elbow of at least 6 weeks duration who were recruited by family doctors. Patients were randomly allocated to 6 weeks of treatment with corticosteroid injections, physiotherapy, or a wait-and-see policy. Outcome measures included general improvement, severity of the main complaint (pain), elbow disability, and patients satisfaction. The severity of elbow complaints, grip strength, and pressure pain threshold were assessed; all outcomes were assessed at 3, 6, 12, 26, and 52 weeks.

185 patients took part in the study. Corticosteroid injections were substantially better than all other therapy options for all outcome measures at 6 weeks; success rates were 92% compared with 47% for physiotherapy and 32% for wait-and-see policy. However, recurrence rate in the injection group was high. Long-term differences between injections and physiotherapy were significantly in favour of physiotherapy; success rates at 52 weeks were 69% for injections, 91% for physiotherapy, and 83% for a wait-and-see policy. However, the better success rate for physiotherapy over a wait-and-see policy was not statistically significant.

Nynke Smidt Comment
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-0-20-7611-4076
Lancet
21-Feb-2002


Page: 1 2

Related medicine news :

1. Dutch study highlights crying as risk factor for child abuse
2. Controlled study after Dutch caf fire highlights teen mental-health problems after disasters
3. Dutch study links tea drinking to reduced heart attack risk
4. Four researchers awarded Dutch Nobel Prize
5. "Dutch Nobel Prize" for three researchers
6. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
7. UMaine study looks at infants and chronic nighttime crying
8. Chronic pain treatments more effective when taken together, new study shows
9. UNC study: Most N.C. family practitioners engage in unrecognized community service
10. New study in Nature demonstrates protection against cell death during heart attack
11. UCSF study offers insight into human circadian rhythms

Post Your Comments:
(Date:8/22/2014)... Texas (PRWEB) August 23, 2014 ... Industry” is a professional and in-depth research report ... basic Glucose Meter information, including Glucose Meter definition, ... as industry overview. This research covers the international ... global industry analysis covering macroeconomic environment & economic ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Today, Zane ... new guide on Account-Based Health Plans. , According to ... as a strategy to lower the cost of healthcare ... of medical spending accounts, however, can be confusing. , ... to learn the four main types of ABHPs. It ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 MyWriters.com ... is written by marketing experts for marketers to help ... has caught the attention of Shane Michaels, prompting an ... Internet marketing in any way knows that content is ... the industry,” reports Michaels. “But even though content is ...
(Date:8/22/2014)... CA (PRWEB) August 22, 2014 Buying a ... an adult who is unsure about available coverage types by ... providing principal life insurance policy pricing to the public using ... use of this tool is free and is expected to ... available to the public throughout the U.S. The system is ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Millennium Treatment Group ... resulting in a high level of drug use among teenagers. ... fight against drug addiction and work to minimize drug abuse. ... of alcohol and drug addiction in history. According to the ... estimated 23.9 million Americans aged 12 or older—or 9.2 percent ...
Breaking Medicine News(10 mins):Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2
(Date:8/21/2014)... , N.Y. and HAMBURG, Germany , ... announced it is collaborating with Deutsches Elektronen-Synchrotron ( DESY ... Germany , to speed up management and storage ... Big Data and Analytics architecture based on IBM ... per second of data at peak performance and help ...
(Date:8/21/2014)... 21, 2014  Zacks.com announces the list of stocks featured ... analysts discuss the latest news and events impacting stocks and ... Hewlett-Packard (NYSE: HPQ - Free Report ), IBM (NYSE: ... SB - Free Report ), GlaxoSmithKline plc (NYSE: ... FI - Free Report ). Today, Zacks ...
(Date:8/21/2014)... , Aug. 21, 2014  Henry Schein, Inc. (NASDAQ: ... care products and services to office-based dental, animal health and ... two investor conferences in September: , September 4, ... York , NY at 12:50 p.m. ET , September ... in New York , NY at 1:25 p.m. ...
Breaking Medicine Technology:DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11Henry Schein To Present At Two Investor Conferences In September 2
Cached News: